Navigation Links
'Hub' of fear memory formation identified in brain cells
Date:9/28/2008

A protein required for the earliest steps in embryonic development also plays a key role in solidifying fear memories in the brains of adult animals, scientists have revealed. An apparent "hub" for changes in the connections between brain cells, beta-catenin could be a potential target for drugs to enhance or interfere with memory formation.

The results are published online this week and appear in the October issue of Nature Neuroscience.

The protein beta-catenin acts like a Velcro strap, fastening cells' internal skeletons to proteins on their external membranes that connect them with other cells. In species ranging from flies to frogs to mice, it also can transmit early signals that separate an embryo into front and back or top and bottom.

During long-term memory formation, structural changes take place in the synapses the connections between neurons in the brain, says Kerry Ressler, MD, PhD, associate professor of psychiatry and behavioral sciences at Emory University School of Medicine. Ressler is a researcher at Emory University's Yerkes National Primate Research Center, where the research was conducted, and a Howard Hughes Medical Institute investigator.

"We thought beta-catenin could be a hub for the changes that take place in the synapses during memory formation," says Ressler. "But because beta-catenin is so important during development, we couldn't take the standard approach of just knocking it out genetically."

He and graduate student Kimberly Maguschak used a variety of approaches to probe beta-catenin's role in fear memory formation, such as stabilizing the protein with a pulse of the psychiatric drug lithium and injecting a virus that could remove the gene for beta-catenin from brain cells.

If mice are electrically shocked just after they hear a certain tone, they gradually learn to fear that tone, and they show that fear by freezing.

To test beta-catenin's involvement in fear memory, Maguschak used a genetically engineered virus paired with mice that had the DNA around their beta-catenin genes modified. Once a cell is infected, the virus deletes the beta-catenin gene so that the cell can't make beta-catenin protein. She injected the virus into the amygdala, a part of the brain thought to be important for forming memories of emotionally charged events.

"We found that after beta-catenin is taken out, the mice can still learn to fear the shocks," says Maguschak. "But two days later, their fear doesn't seem to be retained because they spend half as much time freezing in response to the tone."

Beta-catenin appears to be turned on in the amygdala and involved in signaling during the learning process, Maguschak says.

"However, after the process of moving memories from short-term to long-term is complete, beta-catenin doesn't appear to be necessary anymore," she notes. "Injecting the virus after that point has no effect on the ability of the mice to express their fear memory."

Maguschak also found that lithium salts, when given to the mice before training, make them even more afraid of the tone two days later. Chemically, lithium inhibits an enzyme that usually targets beta-catenin for destruction, causing beta-catenin to become more active. She cautions that lithium is an imprecise tool for studying beta-catenin because it affects several enzymes in the brain.

"Psychiatrists have used lithium to treat mania and bipolar disorder for decades, but how it works is not well-understood," Ressler says. "Importantly, we gave the mice one acute dose of lithium, rather than letting it build to a stable level like in the clinical situation. It's not clear whether there is a connection between mood regulation and how lithium functions in our experiments with fear memory."

The authors suggest medications that inhibit beta-catenin could transiently interfere with memory formation after trauma, helping to prevent post-traumatic stress disorder. Conversely, drugs that enhance beta-catenin function within the brain might serve as new therapies to treating disorders of memory, such as Alzheimer's disease. Besides lithium, no drugs that target beta-catenin are available.

Ressler says his team's next step is to dissect the contribution of beta-catenin's different functions: cell adhesion and developmental signaling. He notes that when over-activated by genetic mutations, beta-catenin can drive tumor formation in several tissues, such as the colon, the skin and the kidney.

"It's possible we will see that a number of genes involved in cancer also are involved in learning and memory," he says.


'/>"/>

Contact: Kathi Baker
kobaker@emory.edu
404-727-9371
Emory University
Source:Eurekalert

Related medicine news :

1. Joint NJ/NY Rally for Addiction Recovery to Be Hub of Events Nationwide
2. Chubby Checker Adds Twist to 10,000 Strong at Ninth Annual Walk to Cure Cancer for UMass Memorial Cancer Center at the UMass Medical School
3. Federal Labor Law Violations Provoke Teamster Strike at AmerisourceBergen Northwest Distribution Hub
4. Founding CEOS of SureScripts(R) and RxHub(R) Join Forces to Deliver Clinical Information Technology Services to Physician Practices
5. Epilepsy marked by neural hub network
6. Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality
7. AVMA Launches Animal Welfare Web Section to Provide Hub for Programs and Information
8. Chubb Expects to Release Earnings on July 24 and Hold Conference Call on the Same Day
9. HUB International New England Reminds Massachusetts Boaters that Safety is Paramount This Summer
10. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
11. Removing Ovaries Before Menopause Leads to Memory, Movement Troubles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical Products, ... nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product ... a newly patented safety device secured by nasal surgeons onto the floor of the ...
(Date:4/29/2016)... ... 29, 2016 , ... Regenerative Medicine Solutions (RMS) scored 94.8124 out ... earning them second place for Tampa’s Best Places to Work. They were ranked in ... a great accomplishment for our team,” says RMS Human Resources Manager Irene Miller. “We ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... promote their animal line of probiotics, Petbiotics ™, as they fondly call ... of animal rescue groups networking for their non-profit organizations. Animal rescues across the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions is pleased to ... Dynamics GP for one their long-term care clients. Working together with the clients ... key clinical management systems, and delivered a fully integrated accounting and business-management solution ...
(Date:4/29/2016)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... saying it is time to set the record straight. Traditionally, BC and AD has ... possibly be true and offers explanation. , “To start with, the Name of the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
(Date:4/27/2016)... Avril 2016   ... +5% sur le trimestre, soutenu par une croissance ... Croissance de +16% des ventes aux hôpitaux ... Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventeur ... aujourd,hui son chiffre d,affaires pour le premier trimestre ...
Breaking Medicine Technology: